ZCCHC7

Summary

ZCCHC7 (zinc finger CCHC-type containing 7, HGNC:26209) is a protein-coding gene on chromosome 9p13.2, encoding Zinc finger CCHC domain-containing protein 7 (Q8N3Z6).

Enables RNA binding activity. Predicted to be involved in nuclear RNA surveillance. Located in cytosol and nucleolus.

Source: NCBI Gene 84186 — RefSeq curated summary.

At a glance

• GWAS associations: 14
• Clinical variants (ClinVar): 92 total
• MANE Select transcript: NM_032226

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26209
Approved symbol	ZCCHC7
Name	zinc finger CCHC-type containing 7
Location	9p13.2
Locus type	gene with protein product
Status	Approved
Aliases	FLJ22611, AIR1
Ensembl gene	ENSG00000147905
Ensembl biotype	protein_coding
Entrez	84186

Gene structure

Transcript identifiers

Ensembl transcripts: 32 — 26 protein_coding, 6 protein_coding_CDS_not_defined

ENST00000322831, ENST00000336755, ENST00000461038, ENST00000463625, ENST00000481507, ENST00000488607, ENST00000496099, ENST00000497924, ENST00000534928, ENST00000908248, ENST00000908249, ENST00000908250, ENST00000908251, ENST00000908252, ENST00000908253, ENST00000908254, ENST00000908255, ENST00000908256, ENST00000908257, ENST00000908258, ENST00000936927, ENST00000936928, ENST00000936929, ENST00000936930, ENST00000936931, ENST00000936932, ENST00000936933, ENST00000936934, ENST00000936935, ENST00000936936, ENST00000936937, ENST00000962617

RefSeq mRNA: 4 — MANE Select: NM_032226 NM_001289119, NM_001289120, NM_001289121, NM_032226

CCDS: CCDS6608

Canonical transcript exons

ENST00000336755 — 9 exons

Exon	Start	End
ENSE00001852696	37120574	37120623
ENSE00003464004	37356835	37358149
ENSE00003464645	37327799	37327834
ENSE00003495130	37126312	37126942
ENSE00003513270	37354710	37354824
ENSE00003587848	37349357	37349452
ENSE00003596114	37304188	37304313
ENSE00003684411	37302188	37302231
ENSE00003721023	37305544	37305714

Expression profiles

Bgee: expression breadth ubiquitous, 245 present calls, max score 97.60.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 20.5201 / max 558.0974, expressed in 1805 samples.

FANTOM5 promoters (10 alternative TSS)

Promoter ID	TPM avg	Samples expressed
96701	20.0834	1805
96720	0.2555	42
96705	0.0529	8
96724	0.0388	7
96706	0.0367	8
96723	0.0184	9
96725	0.0132	5
96707	0.0081	1
96704	0.0075	4
96708	0.0056	2

Top tissues by expression

249 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
calcaneal tendon	UBERON:0003701	97.60	gold quality
tendon	UBERON:0000043	96.70	gold quality
tendon of biceps brachii	UBERON:0008188	95.81	gold quality
oviduct epithelium	UBERON:0004804	95.64	gold quality
buccal mucosa cell	CL:0002336	94.99	gold quality
colonic epithelium	UBERON:0000397	93.23	gold quality
epithelial cell of pancreas	CL:0000083	91.70	gold quality
bone marrow cell	CL:0002092	90.79	gold quality
parotid gland	UBERON:0001831	90.76	gold quality
sural nerve	UBERON:0015488	90.65	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	90.57	gold quality
oocyte	CL:0000023	90.49	gold quality
cartilage tissue	UBERON:0002418	89.78	gold quality
cauda epididymis	UBERON:0004360	88.48	gold quality
caput epididymis	UBERON:0004358	88.21	gold quality
lymph node	UBERON:0000029	87.82	gold quality
ileal mucosa	UBERON:0000331	87.79	gold quality
corpus epididymis	UBERON:0004359	87.77	gold quality
pigmented layer of retina	UBERON:0001782	87.66	gold quality
upper leg skin	UBERON:0004262	87.64	gold quality
cortical plate	UBERON:0005343	87.62	gold quality
pancreatic ductal cell	CL:0002079	87.32	gold quality
bone marrow	UBERON:0002371	87.14	gold quality
superficial temporal artery	UBERON:0001614	87.11	gold quality
adrenal tissue	UBERON:0018303	86.53	gold quality
seminal vesicle	UBERON:0000998	86.30	gold quality
trabecular bone tissue	UBERON:0002483	86.19	gold quality
blood	UBERON:0000178	86.03	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	85.71	gold quality
vermiform appendix	UBERON:0001154	85.60	gold quality

Single-cell (SCXA)

Detected in 11 experiment(s), a significant marker in 9.

Experiment	Marker?	Max mean expression
E-MTAB-10432	yes	587.52
E-CURD-112	yes	485.27
E-HCAD-6	yes	397.06
E-HCAD-4	yes	55.00
E-MTAB-9067	yes	15.94
E-HCAD-10	yes	14.08
E-ANND-3	yes	8.98
E-MTAB-10042	yes	6.50
E-CURD-122	yes	5.68
E-MTAB-7249	no	792.42
E-MTAB-6386	no	260.31

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

44 targeting ZCCHC7, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-1236-3P	99.94	68.04	1695
HSA-MIR-12119	99.87	68.35	1653
HSA-MIR-548AZ-5P	99.83	69.94	3230
HSA-MIR-548T-5P	99.83	69.91	3220
HSA-MIR-6505-5P	99.73	69.25	1595
HSA-MIR-6752-3P	99.72	66.71	1587
HSA-MIR-4729	99.69	72.18	4233
HSA-MIR-3660	99.68	67.33	1149
HSA-MIR-4526	99.68	67.07	1136
HSA-MIR-3158-5P	99.65	67.51	1763
HSA-MIR-7152-5P	99.60	69.33	2094
HSA-MIR-4753-5P	99.54	68.51	1356
HSA-MIR-186-3P	99.51	66.24	1685
HSA-MIR-889-5P	99.41	68.75	1025
HSA-MIR-130A-5P	99.33	70.26	2623
HSA-MIR-6719-3P	99.29	67.78	1387
HSA-MIR-5584-3P	99.23	68.79	1351
HSA-MIR-3925-5P	99.21	67.90	1466
HSA-MIR-4291	99.20	68.88	2969
HSA-MIR-4796-3P	99.08	68.38	1681
HSA-MIR-8070	99.07	69.30	1303
HSA-MIR-376A-3P	99.06	69.17	1128
HSA-MIR-376B-3P	99.06	69.17	1128
HSA-MIR-922	99.02	67.23	1838
HSA-MIR-154-5P	98.92	66.65	733
HSA-MIR-4635	98.74	67.63	1339
HSA-MIR-4742-3P	98.73	69.82	1803
HSA-MIR-4782-5P	98.35	69.33	1474

Literature-anchored findings (GeneRIF, showing 2)

• Data show that sequences 3’ of PAX5 disrupting ASXL1, and ZCCHC7 disrupted by sequences 3’ of FRG1B and LOC1499503. (PMID:19586940)
• We analyzed the interactions of the human TRAMP-like proteins, PAPD5, ZCCHC7, and MTR4, with the nuclear exosome. PAPD5 and ZCCHC7 exhibited mutual interactions in presence of the exosome catalytic subunit RRP6, whereas MTR4 was dispensable for their assembly (PMID:27434818)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	zcchc7	ENSDARG00000055443
mus_musculus	Zcchc7	ENSMUSG00000035649
rattus_norvegicus	Zcchc7	ENSRNOG00000013078

Paralogs (3): ZCCHC9 (ENSG00000131732), CNBP (ENSG00000169714), ZCCHC13 (ENSG00000187969)

Protein

Protein identifiers

Zinc finger CCHC domain-containing protein 7 — Q8N3Z6 (reviewed: Q8N3Z6)

Alternative names: TRAMP-like complex RNA-binding factor ZCCHC7

All UniProt accessions (2): Q8N3Z6, X6R4A7

UniProt curated annotations — full annotation on UniProt →

Subunit / interactions. Component of a nucleolar TRAMP-like complex, an ATP-dependent exosome regulatory complex consisting of a helicase (MTREX), an oligadenylate polymerase (TENT4B or TENT4A), and a substrate specific RNA-binding factor (ZCCHC7 or ZCCHC8). Several TRAMP-like complexes exist with specific compositions and are associated with nuclear, or nucleolar RNA exosomes.

Subcellular location. Nucleus. Nucleolus.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8N3Z6-1	1	yes
Q8N3Z6-2	2

RefSeq proteins (4): NP_001276048, NP_001276049, NP_001276050, NP_115602* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001878	Znf_CCHC	Domain
IPR036875	Znf_CCHC_sf	Homologous_superfamily
IPR051644	TRAMP_AT-DNA-binding	Family

Pfam: PF00098

UniProt features (38 total): cross-link 14, compositionally biased region 6, sequence conflict 5, zinc finger region 4, modified residue 2, splice variant 2, sequence variant 2, region of interest 2, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8N3Z6-F1	53.92	0.00

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (16): 482, 485, 131, 139, 141, 239, 254, 339, 412, 417, 435, 478, 487, 490, 493, 537

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-9930044	Nuclear RNA decay

MSigDB gene sets: 109 (showing top): RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, GOBP_SNO_S_RNA_METABOLIC_PROCESS, GOBP_TRNA_METABOLIC_PROCESS, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, GOBP_RNA_SURVEILLANCE, USF_01, chr9p13, RYTTCCTG_ETS2_B, ELK1_01, REACTOME_METABOLISM_OF_RNA, GOCC_NUCLEOLUS, SCGGAAGY_ELK1_02, MYCMAX_03, MAX_01

GO Biological Process (6): nuclear mRNA surveillance of mRNA 3’-end processing (GO:0071031), nuclear polyadenylation-dependent rRNA catabolic process (GO:0071035), nuclear polyadenylation-dependent snoRNA catabolic process (GO:0071036), nuclear polyadenylation-dependent snRNA catabolic process (GO:0071037), TRAMP-dependent tRNA surveillance pathway (GO:0071038), nuclear polyadenylation-dependent CUT catabolic process (GO:0071039)

GO Molecular Function (5): RNA binding (GO:0003723), zinc ion binding (GO:0008270), nucleic acid binding (GO:0003676), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (4): nucleolus (GO:0005730), cytosol (GO:0005829), TRAMP complex (GO:0031499), nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Metabolism of RNA	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
nuclear RNA surveillance	5
binding	2
nuclear mRNA surveillance	1
nuclear polyadenylation-dependent mRNA catabolic process	1
sno(s)RNA catabolic process	1
poly(A)-dependent snoRNA 3’-end processing	1
snRNA catabolic process	1
tRNA surveillance	1
CUT catabolic process	1
nucleic acid binding	1
transition metal ion binding	1
cation binding	1
nuclear lumen	1
intracellular membraneless organelle	1
cytoplasm	1
cellular anatomical structure	1
nuclear protein-containing complex	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

1914 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZCCHC7	MTREX	P42285	998
ZCCHC7	TENT4A	Q5XG87	997
ZCCHC7	PAPOLA	P51003	995
ZCCHC7	PAPOLG	Q9BWT3	995
ZCCHC7	PAPOLB	Q9NRJ5	995
ZCCHC7	TENT4B	Q8NDF8	995
ZCCHC7	EXOSC10	Q01780	883
ZCCHC7	RBM7	Q9Y580	860
ZCCHC7	ZCCHC8	Q6NZY4	793
ZCCHC7	DIS3	Q9Y2L1	764
ZCCHC7	C1D	Q13901	748
ZCCHC7	ZFC3H1	O60293	716
ZCCHC7	SKIC2	Q15477	715
ZCCHC7	EXOSC1	Q9Y3B2	690
ZCCHC7	SETX	Q7Z333	678

IntAct

87 interactions, top by confidence:

A	B	Type	Score
SART1	PRPF6	psi-mi:“MI:0914”(association)	0.750
RPL10A	RRP8	psi-mi:“MI:0914”(association)	0.640
RPL14	RRP8	psi-mi:“MI:0914”(association)	0.640
NOL12	RRP8	psi-mi:“MI:0914”(association)	0.640
NOP53	RRP8	psi-mi:“MI:0914”(association)	0.640
UBE2I	ZCCHC7	psi-mi:“MI:0915”(physical association)	0.560
ZCCHC7		psi-mi:“MI:0915”(physical association)	0.560
ZCCHC7	CARD9	psi-mi:“MI:0915”(physical association)	0.560
	ZCCHC7	psi-mi:“MI:0915”(physical association)	0.560
ZNF250	ZCCHC7	psi-mi:“MI:0915”(physical association)	0.560
LCE1E	ZCCHC7	psi-mi:“MI:0915”(physical association)	0.560
ZCCHC7	KIF9	psi-mi:“MI:0915”(physical association)	0.560
ZCCHC7	TRIM41	psi-mi:“MI:0915”(physical association)	0.560
ZCCHC7	NEK6	psi-mi:“MI:0915”(physical association)	0.560
ZCCHC7	GIPC2	psi-mi:“MI:0915”(physical association)	0.560
SUMO1	ZCCHC7	psi-mi:“MI:0915”(physical association)	0.560
ZCCHC7	NPM1	psi-mi:“MI:0915”(physical association)	0.540
H1-6	ZNF724	psi-mi:“MI:0914”(association)	0.530
PUM3	RRP8	psi-mi:“MI:0914”(association)	0.530
PPAN	PPM1G	psi-mi:“MI:0914”(association)	0.530
ZCCHC7	RPL13	psi-mi:“MI:0914”(association)	0.530
ABT1	ZNF316	psi-mi:“MI:0914”(association)	0.530

BioGRID (84): ZCCHC7 (Two-hybrid), ZCCHC7 (Two-hybrid), ZCCHC7 (Two-hybrid), ZCCHC7 (Affinity Capture-MS), ZCCHC7 (Affinity Capture-MS), PDLIM7 (Affinity Capture-MS), HDLBP (Affinity Capture-MS), SENP5 (Affinity Capture-MS), EIF2S2 (Affinity Capture-MS), HDGFRP2 (Affinity Capture-MS), ZNHIT6 (Affinity Capture-MS), FAM208A (Affinity Capture-MS), ZCCHC7 (Affinity Capture-MS), ZCCHC7 (Affinity Capture-MS), PDLIM7 (Affinity Capture-MS)

ESM2 similar proteins: A0JNH9, A1L2T6, A2A3V1, A7E3D8, A8MT70, A9C3N6, A9JRX0, B0CM36, B1AX39, B1WC15, E7FAP1, F1R983, O95447, P0DPK0, P23497, P46100, Q09003, Q0IIM1, Q0P5X5, Q28EG9, Q2KIN0, Q3UHX0, Q4R3Q7, Q5H9M0, Q5T5J6, Q5U2Y9, Q5ZLE9, Q66H73, Q6GNV6, Q6GQJ2, Q6IE81, Q6IE82, Q6PG04, Q6ZPI0, Q6ZUT1, Q76FK4, Q7TSG3, Q7YQM3, Q7YQM4, Q80WQ8

Diamond homologs: A1L2T6, B1AX39, B1WC15, Q2KIN0, Q8N3Z6

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
ZCCHC7	“form complex”	“NEXT complex, TENT4B-ZCCHC7 variant”	binding
ZCCHC7	“form complex”	“NEXT complex, TENT4A-ZCCHC7 variant”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 67 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Peptide chain elongation	11	30.3×	2e-12
Viral mRNA Translation	11	30.3×	2e-12
PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA	11	30.0×	2e-12
Selenocysteine synthesis	11	28.8×	2e-12
Eukaryotic Translation Termination	11	28.8×	2e-12
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)	11	28.1×	2e-12
ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA	11	28.1×	2e-12
Formation of a pool of free 40S subunits	11	26.8×	4e-12

GO biological processes:

GO term	Partners	Fold	FDR
cytoplasmic translation	12	36.4×	1e-13
ribosomal large subunit biogenesis	5	36.4×	3e-05
translation	11	18.5×	3e-09
rRNA processing	6	13.9×	4e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

92 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	68
Likely benign	7
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

4451 predictions. Top by Δscore:

Variant	Effect	Δscore
9:37120624:G:GG	donor_gain	1.0000
9:37126310:A:AG	acceptor_gain	1.0000
9:37126311:G:GA	acceptor_gain	1.0000
9:37126311:GC:G	acceptor_gain	1.0000
9:37126311:GCTTC:G	acceptor_gain	1.0000
9:37302182:TTGTA:T	acceptor_loss	1.0000
9:37302183:TGTAG:T	acceptor_loss	1.0000
9:37302184:GTAG:G	acceptor_loss	1.0000
9:37302185:TA:T	acceptor_loss	1.0000
9:37302186:A:AG	acceptor_gain	1.0000
9:37302186:AGG:A	acceptor_loss	1.0000
9:37302187:G:GG	acceptor_gain	1.0000
9:37302187:G:GT	acceptor_loss	1.0000
9:37302228:TGAGG:T	acceptor_loss	1.0000
9:37304184:TTAG:T	acceptor_loss	1.0000
9:37304185:TA:T	acceptor_loss	1.0000
9:37304186:A:AC	acceptor_loss	1.0000
9:37304186:A:AG	acceptor_gain	1.0000
9:37304186:AGGCC:A	acceptor_gain	1.0000
9:37304187:G:GG	acceptor_gain	1.0000
9:37304312:GA:G	donor_gain	1.0000
9:37304314:G:GG	donor_gain	1.0000
9:37305534:C:CA	acceptor_gain	1.0000
9:37305541:T:G	acceptor_gain	1.0000
9:37305542:A:AG	acceptor_gain	1.0000
9:37305543:G:GA	acceptor_gain	1.0000
9:37305543:GAAA:G	acceptor_gain	1.0000
9:37305710:CAGAT:C	donor_gain	1.0000
9:37305711:AGAT:A	donor_gain	1.0000
9:37305712:GAT:G	donor_gain	1.0000

AlphaMissense

3617 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:37304286:T:A	H251Q	0.993
9:37304286:T:G	H251Q	0.993
9:37304260:T:A	C243S	0.991
9:37304260:T:C	C243R	0.991
9:37304261:G:C	C243S	0.991
9:37327814:T:A	W323R	0.991
9:37327814:T:C	W323R	0.991
9:37327816:G:C	W323C	0.991
9:37327816:G:T	W323C	0.991
9:37304299:T:C	C256R	0.990
9:37327822:G:C	Q325H	0.990
9:37327822:G:T	Q325H	0.990
9:37304262:T:G	C243W	0.989
9:37304269:T:A	C246S	0.989
9:37304270:G:C	C246S	0.989
9:37126858:T:A	W176R	0.988
9:37126858:T:C	W176R	0.988
9:37327819:G:C	R324S	0.988
9:37327819:G:T	R324S	0.988
9:37302205:T:A	W210R	0.987
9:37302205:T:C	W210R	0.987
9:37304261:G:A	C243Y	0.987
9:37304299:T:A	C256S	0.987
9:37304300:G:C	C256S	0.987
9:37126862:T:C	M177T	0.986
9:37327826:C:G	H327D	0.986
9:37304284:C:G	H251D	0.985
9:37304301:C:G	C256W	0.985
9:37327818:G:C	R324T	0.985
9:37305688:T:A	C309S	0.984

dbSNP variants (sampled 300 via entrez): RS1000003440 (9:37123436 A>G), RS1000022929 (9:37351180 C>T), RS1000029438 (9:37148641 T>C), RS1000037542 (9:37147237 G>A), RS1000038246 (9:37306923 G>C), RS1000045184 (9:37165158 A>G,T), RS1000060484 (9:37208338 G>A), RS1000062072 (9:37138377 G>A), RS1000063699 (9:37355774 GA>G,GAA), RS1000091632 (9:37129735 A>G,T), RS1000095712 (9:37260712 C>A), RS1000106220 (9:37195242 C>T), RS1000139970 (9:37261081 C>T), RS1000162697 (9:37141980 A>G), RS1000171911 (9:37214328 C>T)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

14 associations (top):

Study	Trait	p-value
GCST002818_5	HIV-1 susceptibility	4.000000e-07
GCST002818_7	HIV-1 susceptibility	5.000000e-07
GCST007565_167	Morning person	2.000000e-16
GCST007565_180	Morning person	4.000000e-17
GCST007565_33	Morning person	1.000000e-16
GCST007576_252	Chronotype	4.000000e-17
GCST007930_26	Medication use (agents acting on the renin-angiotensin system)	4.000000e-08
GCST008103_35	Bipolar disorder	8.000000e-08
GCST008521_10	Bitter beverage consumption	8.000000e-06
GCST008869_3	Metabolite risk score for predicting weight gain	4.000000e-07
GCST009088_3	Severe bacterial meningitis	7.000000e-07
GCST009600_29	Anorexia nervosa, attention-deficit/hyperactivity disorder, autism spectrum disorder, bipolar disorder, major depression, obsessive-compulsive disorder, schizophrenia, or Tourette syndrome (pleiotropy)	4.000000e-08
GCST011350_17	C-reactive protein levels	9.000000e-10
GCST012465_61	Bipolar disorder	2.000000e-08

EFO canonical traits (7, from GWAS)

EFO ID	Trait name
EFO:0000180	HIV-1 infection
EFO:0008328	chronotype measurement
EFO:0009931	Agents acting on the renin-angiotensin system use measurement
EFO:0010089	bitter beverage consumption measurement
EFO:0004566	body weight gain
EFO:0004725	metabolite measurement
EFO:0004458	C-reactive protein measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

54 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
methylmercuric chloride	decreases expression, affects cotreatment	3
trichostatin A	affects cotreatment, increases expression	3
sodium arsenite	decreases expression, affects cotreatment, increases abundance, increases expression	3
Air Pollutants	affects cotreatment, decreases expression, increases abundance, affects expression, increases expression	3
Valproic Acid	affects expression, decreases expression, increases expression	3
Ozone	affects cotreatment, decreases expression, increases abundance, affects expression	2
Tretinoin	decreases expression	2
Cyclosporine	increases expression	2
Particulate Matter	increases expression, decreases expression, decreases reaction, increases abundance	2
FR900359	decreases phosphorylation	1
bisphenol F	affects cotreatment, increases expression	1
TAK-243	increases sumoylation	1
alpha-pinene	affects cotreatment, decreases expression, increases abundance	1
testosterone undecanoate	affects cotreatment, decreases expression	1
arsenite	affects binding, increases reaction	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
manganese chloride	increases abundance, increases expression, affects cotreatment	1
methacrylaldehyde	affects cotreatment, decreases expression, increases abundance	1
beta-methylcholine	affects expression	1
perfluorooctane sulfonic acid	increases expression	1
monomethylarsonous acid	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression, increases expression	1
abrine	increases expression	1
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	decreases expression, decreases reaction	1
dorsomorphin	affects cotreatment, decreases expression, increases expression	1
Resveratrol	increases expression	1
Temozolomide	increases expression	1
Sunitinib	increases expression	1
Acrolein	affects cotreatment, decreases expression, increases abundance	1
Arsenic	affects cotreatment, increases abundance, increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.